Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 18;398(10305):1041-1042.
doi: 10.1016/S0140-6736(21)01891-2. Epub 2021 Aug 17.

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Georg Mn Behrens  1 , Anne Cossmann  2 , Metodi V Stankov  2 , Inga Nehlmeier  3 , Amy Kempf  3 , Markus Hoffmann  4 , Stefan Pöhlmann  4
Affiliations
Comment

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Georg Mn Behrens et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. The work presented in this Correspondence was supported by the German Center for Infection Research and the Federal Ministry of Education and Research, the Ministry for Science and Culture of Lower Saxony, and the German Research Foundation. The funders had no role in study design, data collection, data analysis, interpretation, writing, or submission of the Correspondence. Further details about contributors and acknowledgements are available in the appendix.

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121–130. - PMC - PubMed
    1. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv. 2021 doi: 10.1101/2021.05.19.21257334. published online June 2. (preprint). - DOI - PMC - PubMed
    1. Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021 doi: 10.1038/s41591-021-01449-9. published online July 14. - DOI - PMC - PubMed
    1. Normark J, Vikström L, Gwon Y-D, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. N Engl J Med. 2021 doi: 10.1056/NEJMc2110716. published online July 14. - DOI - PMC - PubMed
    1. Duarte-Salles T, Prieto-Alhambra D. Heterologous vaccine regimens against COVID-19. Lancet. 2021;398:94–95. - PMC - PubMed